Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05082142
Other study ID # STU00215134
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 17, 2021
Est. completion date December 14, 2022

Study information

Verified date April 2024
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP). The investigators attempt to perform HoLEP as a same-day discharge (SDD) procedure, but at Northwestern Memorial, the SDD rate is currently approximately 60%. The limiting factor in SDD is hematuria. Tranexamic acid (TXA) is a clot promoting drug that is commonly used by orthopedic, cardiac and obstetric surgeons to prevent bleeding. The primary outcome will be to assess if there is a difference in SDD rates in those who receive TXA vs. those who do not. Secondary outcomes will assess bleeding complications (defined as unplanned ED visit/clinic visit/procedure/admission related to bleeding, clot retention, clot evacuation, need for perioperative transfusion) between participants who receive TXA vs. those do not. The study will also assess differences in perioperative complications associated with TXA including but not limited to: deep venous thrombosis, pulmonary embolism, cerebrovascular events, between the groups. The study will also assess for the duration of postoperative hematuria between groups as well as differences in operative times between the groups. The investigators anticipate that there may be up to a 25% increase in SDD rates in those who receive TXA vs. those who do not.


Description:

On the day of the surgery, the treatment assigned to the participant will be determined by chance, like flipping a coin. One arm will undergo the HoLEP procedure while receiving 1g TXA IV intraoperatively. The second arm will undergo the HoLEP procedure without receiving TXA IV intraoperatively. After surgery, participants will receive weekly surveys via text message or email asking them to report any instances of difficulty urinating or blood in the urine. These surveys will continue for 12 weeks. 30 days after surgery, participants will come in for a standard clinical follow up appointment where they will be asked to complete a questionnaire about bleeding complications and symptoms. 12 weeks after surgery, participants will come in for their 12-week follow up and will be assessed for benign prostate hyperplasia (BPH) symptoms and their urine flow rate will be measured.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date December 14, 2022
Est. primary completion date June 15, 2022
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - Males 18-89 undergoing HoLEP - Willing to sign the Informed Consent Form - Able to read, understand, and complete patient questionnaires, pain texts, and medication diary Exclusion Criteria: - Allergy or hypersensitivity to TXA, history of acute venous or arterial thrombosis, intrinsic risk for thrombosis or thromboembolism, history of thromboembolic disease, hereditary thrombophilia, use of hormonal agents - Patients having any additional simultaneous procedure other than a HoLEP (cystolitholapaxy allowed). - Anticipated need for perineal urethrostomy at the time of HoLEP - Patient not undergoing catheter removal and voiding trial at Northwestern Memorial Hospital

Study Design


Intervention

Drug:
Tranexamic acid
Patients in the intervention arm will receive 1g of intraoperative IV TXA during the HoLEP procedure.

Locations

Country Name City State
United States Northwestern University Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Same-day Discharge Rate Number of participants who are discharged on the same day and have same-day catheter removal. Day 0-1
Primary Length of Stay Post-operative to discharge home Day 0-1
Primary Same Day Discharge 24 hours
Secondary Number of Participants With Bleeding Complications Participants who have bleeding complications (defined as unplanned ED visit/clinic/procedure/admission related to bleeding, clot retention, clot evacuation, need for perioperative transfusion). This will be assessed by a weekly survey distributed to participants for 12 weeks. 12 weeks
Secondary Duration of Postoperative Hematuria Days participants have postoperative hematuria. This will be assessed by a weekly survey distributed to participants for 12 weeks. 12 weeks
Secondary Operative Times Operative times during HoLEP procedure. Day 0
Secondary Adverse Events Related to TXA Number of participants who have adverse events related to TXA (thrombotic events (DVT, PE, stroke), seizures). 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06397287 - PROM Project Urology
Completed NCT03572348 - VeSpAR: Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Strictures. N/A
Completed NCT03339609 - Uroflow Measurement With Electromyography (EMG) to Identify Lower Urinary Tract Symptoms (LUTS): Conducted on Healthy Children N/A
Active, not recruiting NCT01529658 - Renal Hypothermia During Partial Nephrectomy N/A
Completed NCT03668262 - ED50 of Cis-atracurium for Laryngeal Mask Incubation in General Anesthesia
Recruiting NCT04763538 - Quality and Outcome Measurements of Urological Patients
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT05032287 - Medical Expulsive Therapy Post-SWL For Renal Stones N/A
Active, not recruiting NCT03243682 - The Alternating Bidirectional Versus The Standard Approach During Shock Wave Lithotripsy For Renal And Upper Lumbar Ureteric Stones N/A
Recruiting NCT05169892 - Aquablation in Benign Prostatic Hyperplasia in Canada
Enrolling by invitation NCT03234543 - Remote Ischemic Conditioning in Abdominal Surgery N/A
Recruiting NCT05201131 - Canadian Cohort of Convective Thermal Therapy Using Rezūm System in Benign Prostatic Hyperplasia (BPH).
Recruiting NCT06187870 - Bank of Biological Material From Patients and Healthy Donors for the Study of Urological and Uro-oncological Pathologies
Completed NCT03847909 - A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 Phase 2
Recruiting NCT04972890 - The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction Phase 2/Phase 3
Not yet recruiting NCT03258658 - Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures Phase 1
Terminated NCT02543645 - A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Phase 1
Terminated NCT03843073 - Connected Catheter- Safety and Effectiveness Study N/A
Terminated NCT04826484 - Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel Phase 3
Terminated NCT04059159 - Connected Catheter - Safety and Effectiveness Study N/A